Veeva and OpenEvidence Announce Long-Term Partnership for Open Vista
Introduction
In a significant development for the healthcare and pharmaceutical industries, Veeva Systems and OpenEvidence have officially announced a long-term partnership aimed at creating and commercializing an innovative platform known as Open Vista. This collaboration is set to harness the power of artificial intelligence (AI) to improve patient access to clinical trials and accelerate drug discovery, ultimately leading to better health outcomes.
The Vision Behind Open Vista
Open Vista seeks to address critical gaps in the healthcare system, particularly for patients suffering from severe diseases who have exhausted standard treatment options. By leveraging AI capabilities, the platform will facilitate connections between healthcare providers and patients, guiding them to relevant clinical trials and advanced therapies. OpenEvidence has established itself as a leader in clinical decision support, with over 40% of U.S. physicians actively utilizing its AI-driven tools at the point of care. According to Daniel Nadler, CEO of OpenEvidence, the partnership with Veeva represents a game-changing opportunity to further bridge the gap between peer-reviewed evidence and real-world clinical practice. This initiative aims to streamline the transition of medical research into practical treatments that benefit patients at their bedside.
Capabilities of the Partnership
The partnership aims to leverage AI to enhance how biopharmaceutical companies connect with healthcare professionals and patients. Peter Gassner, CEO of Veeva, emphasized the synergy between Veeva and OpenEvidence, noting that this collaboration is aligned with the emerging era of AI-driven life sciences. By merging their expertise, the companies aim to accelerate the development of effective new treatments, broaden patient participation in clinical trials, and enhance understanding and adoption of existing approved medications.
The Impact on Patients and Healthcare Providers
For many patients facing grave illnesses, clinical trials often represent the most promising avenue for care. Open Vista is envisioned as a tool that not only identifies pertinent clinical trials but also improves patient recruitment, which can lead to faster and more effective treatment solutions. The anticipated outcome is a healthcare landscape where patients have better access to clinical trials and are more informed about the therapies available to them.
Timeline for Open Vista Launch
The launch of Open Vista is scheduled for 2026, with both Veeva and OpenEvidence committed to ensuring that the platform is equipped with the latest advancements in AI technology. This timeline reflects their dedication to thorough development and regulatory compliance, ensuring that the platform meets the highest standards of safety and effectiveness for end-users.
About Veeva Systems
Veeva Systems is a leading provider of cloud-based solutions tailored for the life sciences sector. Their commitment to innovation and excellence significantly benefits over 1,500 clients ranging from top global biopharma companies to emerging biotech firms. The company prioritizes the interests of all stakeholders – clients, employees, shareholders, and the industry at large.
About OpenEvidence
OpenEvidence has become the fastest-growing clinical decision support platform in the U.S., being the most utilized medical search engine by American clinicians. Hundreds of thousands of verified healthcare professionals rely on OpenEvidence for making critical clinical decisions based on peer-reviewed medical literature. The platform is actively employed by over 10,000 hospitals and healthcare centers in the U.S., serving the information needs of more than 40% of U.S. physicians.
Conclusion
As we look towards the future of healthcare, the partnership between Veeva and OpenEvidence symbolizes an important stride towards integrating innovative technologies in clinical practice. Open Vista holds the potential to transform patient care by ensuring that critical medical research is efficiently translated into actionable insights and therapies. This alliance stands to significantly influence the landscape of clinical trials and drug discovery in the coming years.
In a significant development for the healthcare and pharmaceutical industries, Veeva Systems and OpenEvidence have officially announced a long-term partnership aimed at creating and commercializing an innovative platform known as Open Vista. This collaboration is set to harness the power of artificial intelligence (AI) to improve patient access to clinical trials and accelerate drug discovery, ultimately leading to better health outcomes.
The Vision Behind Open Vista
Open Vista seeks to address critical gaps in the healthcare system, particularly for patients suffering from severe diseases who have exhausted standard treatment options. By leveraging AI capabilities, the platform will facilitate connections between healthcare providers and patients, guiding them to relevant clinical trials and advanced therapies. OpenEvidence has established itself as a leader in clinical decision support, with over 40% of U.S. physicians actively utilizing its AI-driven tools at the point of care. According to Daniel Nadler, CEO of OpenEvidence, the partnership with Veeva represents a game-changing opportunity to further bridge the gap between peer-reviewed evidence and real-world clinical practice. This initiative aims to streamline the transition of medical research into practical treatments that benefit patients at their bedside.
Capabilities of the Partnership
The partnership aims to leverage AI to enhance how biopharmaceutical companies connect with healthcare professionals and patients. Peter Gassner, CEO of Veeva, emphasized the synergy between Veeva and OpenEvidence, noting that this collaboration is aligned with the emerging era of AI-driven life sciences. By merging their expertise, the companies aim to accelerate the development of effective new treatments, broaden patient participation in clinical trials, and enhance understanding and adoption of existing approved medications.
The Impact on Patients and Healthcare Providers
For many patients facing grave illnesses, clinical trials often represent the most promising avenue for care. Open Vista is envisioned as a tool that not only identifies pertinent clinical trials but also improves patient recruitment, which can lead to faster and more effective treatment solutions. The anticipated outcome is a healthcare landscape where patients have better access to clinical trials and are more informed about the therapies available to them.
Timeline for Open Vista Launch
The launch of Open Vista is scheduled for 2026, with both Veeva and OpenEvidence committed to ensuring that the platform is equipped with the latest advancements in AI technology. This timeline reflects their dedication to thorough development and regulatory compliance, ensuring that the platform meets the highest standards of safety and effectiveness for end-users.
About Veeva Systems
Veeva Systems is a leading provider of cloud-based solutions tailored for the life sciences sector. Their commitment to innovation and excellence significantly benefits over 1,500 clients ranging from top global biopharma companies to emerging biotech firms. The company prioritizes the interests of all stakeholders – clients, employees, shareholders, and the industry at large.
About OpenEvidence
OpenEvidence has become the fastest-growing clinical decision support platform in the U.S., being the most utilized medical search engine by American clinicians. Hundreds of thousands of verified healthcare professionals rely on OpenEvidence for making critical clinical decisions based on peer-reviewed medical literature. The platform is actively employed by over 10,000 hospitals and healthcare centers in the U.S., serving the information needs of more than 40% of U.S. physicians.
Conclusion
As we look towards the future of healthcare, the partnership between Veeva and OpenEvidence symbolizes an important stride towards integrating innovative technologies in clinical practice. Open Vista holds the potential to transform patient care by ensuring that critical medical research is efficiently translated into actionable insights and therapies. This alliance stands to significantly influence the landscape of clinical trials and drug discovery in the coming years.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.